RxDoctor Payments DataLook up a doctor →

Ryan Zuzek, MD

Interventional Cardiology · Pittsburgh, PANPI 1245456284

Payments from drug & device makers

$152,419in general payments, 2019–2025

Across 786 payments — averaging $193.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$36K
  • Amgen$32K
  • Esperion Therapeutics, Inc.$25K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
  • Novartis$13K
  • Sanofi-aventis U.S. LLC$7K
  • plus $24K from 44 others

What the payments were for

  • Consulting fees$35,81623%
  • Speaking & faculty fees$83,71955%
  • Travel & lodging$10,0737%
  • Food & beverage$22,61015%
  • Education$2020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,419 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$188,944
Medicare patients
879
Services billed
2,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban782$785,504
EntrestoSacubitril/Valsartan237$270,139
XareltoRivaroxaban173$185,777
Repatha SureclickEvolocumab231$135,633
JardianceEmpagliflozin38$47,841
Ambrisentan12$33,992
FarxigaDapagliflozin Propanediol42$28,521
Tadalafil12$27,231
Praluent PenAlirocumab25$18,290
BrilintaTicagrelor17$12,752
Metoprolol Succinate896$12,587
Amiodarone Hcl228$7,400
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,304
Flecainide Acetate129$7,046
Atorvastatin Calcium726$7,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$634$785,504782 claims
NovartisEntresto$12,885$270,139237 claims
Johnson & JohnsonXarelto$4,985$185,777173 claims
Boehringer IngelheimJardiance$158$47,84138 claims
AstraZenecaFarxiga, Brilinta$525$41,27359 claims
Esperion Therapeutics, Inc.Nexletol$25,358$4,45112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →